Fakty i mity na temat inozyny Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
lis 30, 2023
Słowa kluczowe:
pranobeks inozyny, leczenie przeciwwirusowe, bezpieczeństwo, skuteczność
##plugins.themes.bootstrap3.article.main##
Abstrakt
Pranobeks inozyny to lek o działaniu immunostymulującym i przeciwwirusowym, od ponad 50 lat wykorzystywany w terapii infekcji wirusowych górnych dróg oddechowych i opryszczki. W tym czasie zebrano wiele doświadczeń związanych z jego zastosowaniem i bezpieczeństwem. Przyczyniły się one do powstania wielu faktów i mitów na temat jego bezpieczeństwa i skuteczności. W niniejszej pracy analizujemy najważniejsze z nich.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Sapilak , B. J. (2023). Fakty i mity na temat inozyny . Medycyna Faktów , 16(3(60), 353-356. https://doi.org/10.24292/01.MF.0323.13
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. pharmindex.pl (access: 20.07.2023).
2. Baza Leków. Groprinosin. (access: 20.07.2023).
3. McCarthy MT, Lin D, Soga T et al. Inosine pranobex enhances human NK cell cytotoxicity by inducing metabolic activation and NKG2D ligand expression. Eur J Immunol. 2020; 50(1): 130-7. http://doi.org/10.1002/eji.201847948.
4. Krastev Z, Jelev D, Ivanova R. Isoprinosine induces a rapid lympho-mononuclear response in adult participants. Med Inf. 2015; 2(1): 80-5.
5. Corey L, Chiang W, Reeves W et al. Effect of isoprinosine on the cellular immune response in initial genital herpes virus infection. Clin Res. 1979; 27: 41A.
6. Galbraith GM, Thiers BH, Fudenberg HH. An open-label trial of immunomodulation therapy with inosiplex (Isoprinosine) in patients with alopecia totalis and cell-mediated immunodeficiency. J Am Acad Dermatol. 1984; 11(2): 224-30.
7. Lowy M, Ledoux-Corbusier M, Achten G et al. Clinical and immunologic response to Isoprinosine in alopecia areata and alopecia universalis: association with autoantibodies. J Am Acad Dermatol. 1985; 12(1): 78-84.
8. Wybran J, Schandene L. Isoprinosine in aphthous stomatitis: clinical improvement associated with enhancement of IL2 production. Int J Immunopharmacol. 1985; 7(3): 318.
9. Dabrowska-Bernstein B, Stasiak A, Dabrowski M et al. Evaluation of the treatment of chronic active hepatitis (HBsAg?) with Isoprinosine. II. Immunological studies. Pol Tyg Lek. 1990; 45(16-18): 347-51.
10. Cianciara J, Laskus T, Gabinska E et al. Isoprinosine in the treatment of chronic active hepatitis type B. Scand J Infect Dis. 1990; 22(6): 645-8.
11. Schinazi RF, Cannon DL, Arnold BH et al. Combinations of isoprinosine and 3’-azido-3’-deoxythymidine in lymphocytes infected with human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1988; 32(12): 1784-7.
12. Majewska A, Lasek W, Janyst M et al. Inhibition of adenovirus multiplication by inosine pranobex and interferon α in vitro. Cent Eur J Immunol. 2015; 40(4): 395-9. http://doi.org/10. 5114/ceji.2015.56960.
13. Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother. 2011; 55(2): 459-72. http://doi.org/10.1128/ AAC.00615-10.
14. Gupta R, Warren T, Wald A. Genital herpes. Lancet. 2007; 370(9605): 2127-37. http://doi.org/10.1016/ s0140-6736(07)61908-4.
15. Looker KJ, Magaret AS, May MT et al. Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012. PLoS ONE. 2015; 10(10): e0140765. http://doi.org/10.1371/ journal.pone.0140765.
16. Looker KJ, Magaret AS, Turner KME et al. Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS ONE. 2015; 10(1): e114989. http://doi.org/10.1371/journal. pone.0114989.
17. Majewska A, Lasek W, Młynarczyk G. Pranobeks inozyny – działanie cytotoksyczne oraz wpływ na replikację ludzkich wirusów paragrypy (HPIV-2, HPIV-4), enterowirusów (CA16, EV71) i adenowirusów (HAdV-2, HAdV-5) w badaniu in vitro [Inosine pranobex – cytotoxic activities and effect of on replication of human parainfluenza viruses (HPIV-2, HPIV-4), entroviruses (CA16, EV71) and adenoviruses (HAdV-2, HAdV-5) in vitro]. Med Dosw Mikrobiol. 2015; 67(2): 107-13.
18. Malgouyat J. A new approach to the treatment of genital condyloma in women. Gynecologie. 1983; 34(5): 415-517.
19. Sadoul G, Beuret T. Treatment of cervical and vulvar condylomata by CO2 laser also with a immunostimulant. Rev Fr Gynecol Obstet. 1984; 79(11): 681-4.
20. Beran J, Špajdel M, Slíva J. Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course. Viruses. 2021; 13(11): 2246. http://doi. org/10.3390/v13112246.
21. Beran J, Špajdel M, Katzerová V et al. Inosine Pranobex Significantly Decreased the Case-Fatality Rate among PCR Positive Elderly with SARS-CoV-2 at Three Nursing Homes in the Czech Republic. Pathogens. 2020; 9(12): 1055. http://doi.org/10.3390/pathogens9121055. Erratum in: Pathogens. 2021; 10(9): 1121.
22. Jayanthi CR, Swain AK, Ganga RT et al. Efficacy and Safety of Inosine Pranobex in COVID-19 Patients: A Multicenter Phase 3 Randomized Double-Blind, Placebo-Controlled Trial. Adv Ther (Weinh). 2022: 2200159. http://doi.org/10.1002/adtp.202200159.
23. You Y, Wang L, Li Y et al. Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes labialis and recurrent herpes genitalis in Chinese patients. J Dermatol. 2015; 42(6): 596-601. http://doi.org/10.1111/1346-8138.12845.
24. De Simone C, Famularo G, Tzantzoglou S et al. Inosine pranobex in the treatment of HIV infection: a review. Int J Immunopharmacol. 1991; 13(suppl 1): 19-27. http://doi.org/10.1016/0192-0561(91)90120-v.
25. Beran J, Šalapová E, Špajdel M; Isoprinosine Study (EWO ISO-2014/1) Team. Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study. BMC Infect Dis. 2016; 16(1): 648. http://doi.org/10.1186/s12879-016-1965-5.
26. Wybran J, Appelboom T. Isoprinosine (inosiplex): immunological and clinical effects. Immunomodulation. Boston, MA: Springer; 1984: 363-74.
27. Masihi KN. C7 Anti-infective activity of immunomodulators. Principles of immunopharmacology. Basel: Birkha¨user; 2011: 411-35.
2. Baza Leków. Groprinosin. (access: 20.07.2023).
3. McCarthy MT, Lin D, Soga T et al. Inosine pranobex enhances human NK cell cytotoxicity by inducing metabolic activation and NKG2D ligand expression. Eur J Immunol. 2020; 50(1): 130-7. http://doi.org/10.1002/eji.201847948.
4. Krastev Z, Jelev D, Ivanova R. Isoprinosine induces a rapid lympho-mononuclear response in adult participants. Med Inf. 2015; 2(1): 80-5.
5. Corey L, Chiang W, Reeves W et al. Effect of isoprinosine on the cellular immune response in initial genital herpes virus infection. Clin Res. 1979; 27: 41A.
6. Galbraith GM, Thiers BH, Fudenberg HH. An open-label trial of immunomodulation therapy with inosiplex (Isoprinosine) in patients with alopecia totalis and cell-mediated immunodeficiency. J Am Acad Dermatol. 1984; 11(2): 224-30.
7. Lowy M, Ledoux-Corbusier M, Achten G et al. Clinical and immunologic response to Isoprinosine in alopecia areata and alopecia universalis: association with autoantibodies. J Am Acad Dermatol. 1985; 12(1): 78-84.
8. Wybran J, Schandene L. Isoprinosine in aphthous stomatitis: clinical improvement associated with enhancement of IL2 production. Int J Immunopharmacol. 1985; 7(3): 318.
9. Dabrowska-Bernstein B, Stasiak A, Dabrowski M et al. Evaluation of the treatment of chronic active hepatitis (HBsAg?) with Isoprinosine. II. Immunological studies. Pol Tyg Lek. 1990; 45(16-18): 347-51.
10. Cianciara J, Laskus T, Gabinska E et al. Isoprinosine in the treatment of chronic active hepatitis type B. Scand J Infect Dis. 1990; 22(6): 645-8.
11. Schinazi RF, Cannon DL, Arnold BH et al. Combinations of isoprinosine and 3’-azido-3’-deoxythymidine in lymphocytes infected with human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1988; 32(12): 1784-7.
12. Majewska A, Lasek W, Janyst M et al. Inhibition of adenovirus multiplication by inosine pranobex and interferon α in vitro. Cent Eur J Immunol. 2015; 40(4): 395-9. http://doi.org/10. 5114/ceji.2015.56960.
13. Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother. 2011; 55(2): 459-72. http://doi.org/10.1128/ AAC.00615-10.
14. Gupta R, Warren T, Wald A. Genital herpes. Lancet. 2007; 370(9605): 2127-37. http://doi.org/10.1016/ s0140-6736(07)61908-4.
15. Looker KJ, Magaret AS, May MT et al. Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012. PLoS ONE. 2015; 10(10): e0140765. http://doi.org/10.1371/ journal.pone.0140765.
16. Looker KJ, Magaret AS, Turner KME et al. Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS ONE. 2015; 10(1): e114989. http://doi.org/10.1371/journal. pone.0114989.
17. Majewska A, Lasek W, Młynarczyk G. Pranobeks inozyny – działanie cytotoksyczne oraz wpływ na replikację ludzkich wirusów paragrypy (HPIV-2, HPIV-4), enterowirusów (CA16, EV71) i adenowirusów (HAdV-2, HAdV-5) w badaniu in vitro [Inosine pranobex – cytotoxic activities and effect of on replication of human parainfluenza viruses (HPIV-2, HPIV-4), entroviruses (CA16, EV71) and adenoviruses (HAdV-2, HAdV-5) in vitro]. Med Dosw Mikrobiol. 2015; 67(2): 107-13.
18. Malgouyat J. A new approach to the treatment of genital condyloma in women. Gynecologie. 1983; 34(5): 415-517.
19. Sadoul G, Beuret T. Treatment of cervical and vulvar condylomata by CO2 laser also with a immunostimulant. Rev Fr Gynecol Obstet. 1984; 79(11): 681-4.
20. Beran J, Špajdel M, Slíva J. Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course. Viruses. 2021; 13(11): 2246. http://doi. org/10.3390/v13112246.
21. Beran J, Špajdel M, Katzerová V et al. Inosine Pranobex Significantly Decreased the Case-Fatality Rate among PCR Positive Elderly with SARS-CoV-2 at Three Nursing Homes in the Czech Republic. Pathogens. 2020; 9(12): 1055. http://doi.org/10.3390/pathogens9121055. Erratum in: Pathogens. 2021; 10(9): 1121.
22. Jayanthi CR, Swain AK, Ganga RT et al. Efficacy and Safety of Inosine Pranobex in COVID-19 Patients: A Multicenter Phase 3 Randomized Double-Blind, Placebo-Controlled Trial. Adv Ther (Weinh). 2022: 2200159. http://doi.org/10.1002/adtp.202200159.
23. You Y, Wang L, Li Y et al. Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes labialis and recurrent herpes genitalis in Chinese patients. J Dermatol. 2015; 42(6): 596-601. http://doi.org/10.1111/1346-8138.12845.
24. De Simone C, Famularo G, Tzantzoglou S et al. Inosine pranobex in the treatment of HIV infection: a review. Int J Immunopharmacol. 1991; 13(suppl 1): 19-27. http://doi.org/10.1016/0192-0561(91)90120-v.
25. Beran J, Šalapová E, Špajdel M; Isoprinosine Study (EWO ISO-2014/1) Team. Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study. BMC Infect Dis. 2016; 16(1): 648. http://doi.org/10.1186/s12879-016-1965-5.
26. Wybran J, Appelboom T. Isoprinosine (inosiplex): immunological and clinical effects. Immunomodulation. Boston, MA: Springer; 1984: 363-74.
27. Masihi KN. C7 Anti-infective activity of immunomodulators. Principles of immunopharmacology. Basel: Birkha¨user; 2011: 411-35.